Blodanalyser för att upptäcka bipolär sjukdom?

Over half of the analytes (11/20) in the panel were associated with inflammatory processes. Seven of these analytes are pro-inflammatory mediators and the remaining four are anti-inflammatory (see Table 2). Levels of three of the seven pro-inflammatory analytes (CD40 Ligand, Growth-Regulated alpha protein and Receptor for advanced glycosylation end products) were decreased and in addition, three anti-inflammatory analytes (Carcinoembryonic Antigen, Interleukin-1 receptor antagonist and Interleukin-10) were found to be increased in BD patients. These findings do not support some published results, which report a predominant increase of pro-inflammatory analytes in BD (Barbosa et al., 2014, Rosenblat and McIntyre, 2015, Kupka et al., 2002 and O’Brien et al., 2006). However, a few studies support our findings of an imbalance in pro-inflammatory and anti-inflammatory mediators in BD (Kim et al., 2007 and Knijff et al., 2007). In addition, a recent study also reported elevated levels of carcinoembryonic antigen (CEA) in BD patients (Kaplan et al., 2015). CEA is involved in the activation and production of anti-inflammatory cytokines such as IL-10 (Thomas et al., 2011). The authors suggest that CEA could have utility for diagnosing BP (Kaplan et al., 2015).

A third functional group of changing serum proteins in BD relate to decreased levels of Apolipoprotein A1 and A2 and increased levels of Lipoprotein (a), which facilitate cholesterol and triglyceride transport, but also play a role in regulation of inflammation (Keeney et al., 2013). Decreased levels of Apolipoprotein A1 have been found in serum and cerebrospinal fluid of patients suffering from a wide range of neurodegenerative disorders (Keeney et al., 2013). These findings are also consistent with an increased risk for cardiovascular events in BD, which support the understanding that BD, like many other chronic disorders such as diabetes, cardiovascular disease and neurodegenerative disorders, presents with prominent immune alterations. Interestingly, the immune changes that we identified for bipolar disorder appear to be distinct from those seen in schizophrenia and major depressive disorder (Papakostas et al., 2013, Chan et al., 2015 and Lakka et al., 2002).

Onddruid skrev:Hittade även den här lilla godbiten: http://www.nature.com/neuro/journal/v18/n2/full/nn.3922.html
angående immunsjukdomar och bipolär sjukdom.